daurisoline has been researched along with Hepatocellular Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Q; Liu, GL; Mu, W; Zhang, JG; Zhang, X; Zhou, HM | 1 |
| Liu, P; Xue, L | 1 |
2 other study(ies) available for daurisoline and Hepatocellular Carcinoma
| Article | Year |
|---|---|
The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib.
Topics: Animals; Benzylisoquinolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Sorafenib | 2021 |
Daurisoline inhibits hepatocellular carcinoma progression by restraining autophagy and promoting cispaltin-induced cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzylisoquinolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Disease Progression; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Nude | 2021 |